Inflammatory Bowel Disease (IBD)
❖ 6·8 million cases of IBD globally, increasing incidence
❖ ~3.0M patients in US with IBD, 40-50% mod to severe
❖ 755,000 new cases/yr
❖ GI Tract fibrosis a major pathobiologic challenge
❖ No curative Rx to date
❖ US ARDS market size $20B annually
❖ IBD growing at ~4-8% per year, large unmet
❖ Market Opportunity
❖ FDA-Approved IBD Therapies
❖ Immune Modulators (AZA, Cyclosporine), Steroids, 5-ASA, Biologics: Humira (TNFa, adaluminab), Remicade (TNFa, Infliximab), Stelara (ustekinumab)
